Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-26-028593
Filing Date
2026-03-16
Accepted
2026-03-16 17:32:27
Documents
4
Period of Report
2026-04-09

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm267779-2_def14a.htm DEF 14A 111699
2 GRAPHIC tm267779d1_pre14aimg001.jpg GRAPHIC 14428
3 GRAPHIC tm267779d1_pre14aproxyimg001.jpg GRAPHIC 266668
4 GRAPHIC tm267779d1_pre14aproxyimg002.jpg GRAPHIC 204284
  Complete submission text file 0001104659-26-028593.txt   782021
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-12584 | Film No.: 26758103
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)